Tiago Henrique

Dr. Tiago Henrique


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Genes
Verified
Journal Article
Open access
PDF file
LSLEONARDO STUCHI
LEONARDO STUCHI
MCMárcia Maria U Castanhole-Nunes
Márcia Maria U Castanhole-Nunes
NMNathália Maniezzo-Stuchi
Nathália Maniezzo-Stuchi
PBPatrícia M. Biselli-Chicote
Patrícia M. Biselli-Chicote
THTiago Henrique
Tiago Henrique
EGEny Maria Goloni-Bertollo
Eny Maria Goloni-Bertollo
Deregulation of VEGFA (Vascular Endothelial Growth Factor A) and NFE2L2 (Nuclear Factor (Erythroid-derived 2)-Like 2), involved in angiogenesis and oxidative stress, can lead to thyroid cancer progression. MiR-17-5p and miR-612 are possible regulators of these genes and may promote thyroid disorders. In order to evaluate the involvement of VEGFA, NFE2L2, hsa-miR-17-5p, and hsa-miR-612 in thyroid pathology, we examined tissue samples from colloid goiter, papillary thyroid cancer (PTC), and a normal thyroid. We found higher levels of VEGFA and NFE2L2 transcripts and the VEGFA protein in goiter and PTC samples than in normal tissue. In the goiter, miR-612 and miR-17-5p levels were lower than those in PTC. Tumors, despite showing lower VEGFA mRNA expression, presented higher VEGFA protein levels compared to goiter tissue. In addition, NRF2 (Nuclear Related Transcription Factor 2) protein levels in tumors were higher than those in goiter and normal tissues. Inhibition of miR-17-5p resulted in reduced NFE2L2 expression. Overall, both transcript and protein levels of NFE2L2 and VEGFA were elevated in PTC and colloid goiter. Hsa-miR-612 showed differential expression in PTC and colloid goiter, while hsa-miR-17-5p showed differential expression only in colloid goiter, suggesting that hsa-miR-17-5p may be a positive regulator of NFE2L2 expression in PTC.

Verified
Journal Article
Open access
PDF file
JGJuliana Prado Gusson-Zanetoni
Juliana Prado Gusson-Zanetoni
LCLuana Pereira Cardoso
Luana Pereira Cardoso
Stefanie Oliveira de SousaStefanie Oliveira de Sousa
Stefanie Oliveira de Sousa
LSLaura Luciana de Melo Moreira Silva
Laura Luciana de Melo Moreira Silva
JMJúlia de Oliveira Martinho
Júlia de Oliveira Martinho
FLFLAVIA CRISTINA RODRIGUES LISONI
FLAVIA CRISTINA RODRIGUES LISONI
Piperine, an active plant alkaloid from black pepper (Piper nigrum), has several pharmacological effects, namely antioxidant, anti-inflammatory and immunomodulatory effects, which involve inhibiting molecular events associated with various stages of cancer development. The aim of this study was to investigate the molecular mechanisms of action of piperine in relation to its potential anticancer effect on head and neck cancer cells. Parameters related to neoplastic potential and cytokine, protein and gene expression were investigated in head and neck cancer cell lines (HEp-2 and SCC-25) treated with piperine. The results of the tests indicated that piperine modified morphology and inhibited viability and the formation of cell colonies. Piperine promoted genotoxicity by triggering apoptosis and cell cycle arrest in the G2/M and S phases. A decrease in cell migration was also observed, and there was decreased expression of MMP2/9 genes. Piperine also reduced the expression of inflammatory molecules (PTGS2 and PTGER4), regulated the secretion of cytokines (IFN-γ and IL-8) and modulated the expression of ERK and p38. These results suggest that piperine exerts anticancer effects on tumor cells by regulating signaling pathways associated with head and neck cancer.